Introduction: Access to antifibrotic medication in the UK for idiopathic pulmonary fibrosis(IPF) and progressive fibrosing interstitial lung disease(PF-ILD) is only available from a tertiary specialist centre, following ILD multi-disciplinary team discussion. Demand to deliver these prescriptions is high. As current UK prescribing regulations have recently changed for IPF patients (Nintedanib for FVC>80% predicted) demand will continue to grow. Our specialist nurse prescribers have been trained to help meet these demands with 2 specialist nurses taking over the responsibility of all follow-up prescriptions. This study aims to investigate the impact this service has had.

Methods: We evaluated the number of prescriptions and counselling sessions led by our Specialist nurses from September 2021-September 2022.Antifibrotic counselling was undertaken using a template formulated by the nursing team encompassing side effects,monitoring requirements and medication delivery. The nurses were also responsible for follow-up sessions to review therapeutic monitoring, side effects and possible drug titration.

Results: A total of 1102 follow-up antifibrotic prescriptions were completed by our 2 specialist nurse prescribers over this 12-month period. 408 patients recieved in-depth counselling sessions with the specialist nursing team using their dedicated counselling proforma. 80% of all antifibrotic prescriptions from our specialist centre were led by specialist nurses.

Conclusion: Specialist nurse prescribers represent an excellent resource to meet UK prescribing regulation demand while providing patients with a single point of access  from counselling to therapeutic monitoring.